I am a medical oncologist who specializes in the care of people with cancers arising in the lungs. In my research, I aim to discover better treatments for individuals with lung cancers by studying the genetic characteristics of their tumors. I lead a research team working to find new genetic targets in cancer cells, and to test anticancer medicines that specifically attack the lung cancers driven by these molecular changes. I work with surgeons and radiation specialists to find the best ways to use surgery, radiotherapy, and drugs together to increase the chance of cure.
I also lead Memorial Sloan Kettering’s project to train IBM’s Watson supercomputer to collect and interpret information about both the person and their cancer to help in selecting the best treatments.
In my practice, I work with two special nurses. Together we strive to fight cancer and to minimize the physical symptoms of cancer so everyone under our care can spend their lives doing what matter most to them.
- Clinical Expertise: Lung Cancer; New Cancer Treatments; Thymoma; Mediastinal Tumors; Control of Side Effects and Physical Problems Caused by Cancer and Cancer Treatments
- Awards and Honors: New York Magazine Top Doctors (2002-2009; 2011-2016)
- Languages Spoken: English
- Education: MD, Cornell University Medical College
- Residencies: Internal Medicine - New York Hospital; Internal Medicine - Memorial Sloan Kettering Cancer Center
- Fellowships: Medical Oncology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Co-Investigated by Mark G. Kris
- A Phase I Study of Certolizumab plus Chemotherapy for Patients with Stage IV Lung Adenocarcinoma
- A Phase I Study of Ramucirumab or Necitumumab plus Osimertinib in Patients with Persistent Non-Small Cell Lung Cancer
- A Phase I/II Study of AP32788 for Patients with Non-Small Cell Lung Cancer
- A Phase I/II Study of Osimertinib and Bevacizumab to Treat Patients with EGFR-Mutant Lung Cancers
- A Phase II Study of Cabozantinib in Patients with Advanced Non-Small Cell Lung Cancer
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more